Examination of the optimal timing of temporary Spinal Cord Stimulation for herpes zoster-associated pain in the subacute phase: Multiinstitutional prospective observational study

Examination of the optimal timing of temporary Spinal Cord Stimulation for herpes zoster-associated pain in the subacute phase: Multiinstitutional prospective observational study - tSCS for subacute ZAP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050704

Enrollment

Registered

2023-04-03

Start date

2023-04-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zoster-Associated Pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who visited the pain outpatient or pain clinic outpatient departments of each research institution among after approval by the ethics committee and 30 June 2025 are affected herpes zoster-associated pain (ZAP) (2) Patients who have ZAP after the onset of herpes zoster between 1-6 months (30-180days) (3) Patients who are affected the cervical or thoracic nerve region and have ZAP resistant to conservative treatment (VAS value more than 50mm) (4) Patients as judged by the study director or co-investigator for tSCS treatment (5) Patients who can voluntarily obtain written consent to participate in the study (6) Patients whose age at the time of obtaining consent is more than 18 years old

Exclusion criteria

Exclusion criteria: (1) Women who are pregnant or may become pregnant (2) Patients whose pain disorder other than ZAP is judged by the principal investigator or co-investigator to affect the evaluation of pain for ZAP (3) Other patients who the Principal Investigator or Co-Investigator deems inappropriate as research subjects.

Design outcomes

Primary

Measure	Time frame
The reduction rate of VAS value between before and after tSCS treatment. If a decrease in VAS value more than 50% is observed, it has a therapeutic effect (EF), and if a decrease in VAS value less than 50% is observed, the treatment effect is poor (NE) . The optimal timing of treatment is determined by divided into two groups; Early Treatment group (ET) , Late Treatment group (LT), depending on the time of start of treatment. We examine the time when the Odd ratio between the EF group and the NE group is maximum.	—

Measure

Time frame

The reduction rate of VAS value between before and after tSCS treatment. If a decrease in VAS value more than 50% is observed, it has a therapeutic effect (EF), and if a decrease in VAS value less than 50% is observed, the treatment effect is poor (NE) . The optimal timing of treatment is determined by divided into two groups; Early Treatment group (ET) , Late Treatment group (LT), depending on the time of start of treatment. We examine the time when the Odd ratio between the EF group and the NE group is maximum.

—

Secondary

Measure	Time frame
We examine the efficiency of the VAS value less than 20mm, HADS and PCS before and after tSCS treatment. We plan to examine changes in EQ-5D levels, analyze factors related to patient information and treatment effect, including spinal MRI findings, and analyze the number of complications associated with tSCS treatment.	—

Countries

Japan

Contacts

Public ContactKyosuke Arakawa

Okayama University Hospital Department of Anesthesiology and Resuscitology

zap_scs_jimukyoku@okayama-u.ac.jp086-235-7330

Outcome results